Screening of Adhatoda vasica Nees as a Putative HIV-protease Inhibitor by , A. Kumar1, K.P. Singh1â€ , B. Upadhyay1*â€ , R. Pra
Journal of Phytology 2010, 2(4): 78–82                                                                                                   ISSN: 2075-6240  
Phytopharmacology                                                                            Available Online: www.journal-phytology.com 
 
REGULAR ARTICLE 
SCREENING OF ADHATODA VASICA NEES AS A PUTATIVE 
HIV-PROTEASE INHIBITOR   
K.P. Singh1†, B. Upadhyay1*†, R. Prasad2, A. Kumar1 
1Biotechnology Lab, P.G. School of Biotechnology and Department of Botany, 
University of Rajasthan, Jaipur 
2Department of Biotechnology, IIT Roorkee, Roorkee, Uttaranchal 
 
SUMMARY 
AIDS remain as one of the greatest public health challenges in the current world’s health 
sector. Adhatoda vasica Nees, is widely used as a folk medicine and in Ayurvedic system 
of medicine in India. As a part of our prescreening program of anti-HIV agents from 
natural sources, various crude extracts of A. vasica were evaluated in-vitro. Pepsin Assay 
as a substitute of HIV-Protease was used for screening HIV-protease inhibitors in this 
experiment. The crude extract of A. vasica exhibited potent inhibitory activity of enzyme 
Pepsin in this assay system, so it might be a potent inhibitor of HIV-Protease which 
belongs to same aspartate family of enzyme and sharing same signature group at the 
active site. 
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1. Introduction 
A large number of research groups is 
actively involved globally in the 
investigation of anti-HIV agents that 
interfere with different stages of HIV 
replicative cycle (Balzarini et al., 1986; Sarin, 
1988). A number of anti-HIV drugs used in 
conventional AIDS therapy are available in 
the market, unfortunately the administration 
of these compounds clinically to the AIDS 
patients exhibited serious side effects 
(Scinazi R et al. 1992). As the data show the 
rapid spread of the AIDS epidemic and the 
appearance of HIV strains resistance to the 
currently available drugs suggests that an 
effective and durable chemotherapy will 
require the use of innovative combinations of 
drugs having diverse mechanism of anti-HIV 
activity (Tantillo et al., 1994; Balzarini et al., 
1996; Lipsky, 1996) and a continuous need 
for alternative inhibitors. New anti-HIV 
agents with such activities may be identified 
through a variety of approaches, one of them 
being screening of natural products. Over the 
last decade, scientific community actively 
involved in antiviral research have also 
turned towards the traditional system of folk 
medicine and Ayurveda, invariably a 
“cocktail” of natural products, to uncover the 
scientific basis of their remedial effects. 
HIV protease was first suggested as a 
potential target for AIDS therapy by Kramer 
(1986), later it was shown that a frame-shift 
mutation in the protease region of the pol-
gene prevented cleavage of the Gag 
polyprotein precursor, which is essential for 
the maturation of the HIV particles. Blockage 
of HIV protease leads to the formation of 
immature non-infectious virions (Kohl, 1988). 
Based on the presence of the 
characteristic signature amino acid sequence, 
Asp-Thr-Gly, was suggested by Toh et al. in 
1985 that the protease of HIV might belong 
to the family of aspartic proteases. This was 
confirmed through pepstatine A inhibition, 
an aspartic protease selective inhibitor, 
(Aoyagi, 1978) and by site-directed 
mutagenesis of the active site Asp 25, which 
led to abolition of the catalytic activity 
(Seelmeier, 1988). The aspartic proteases are 
well characterized group of enzymes that can 
be found in vertebrates, plants, in addition to 
in fungi. Examples of proteases from the 
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aspartic protease class are pepsin, cathepsin 
D, renin, chymosin, penicillopepsin, and 
Rhizopus pepsin, which are two-domain 
enzymes with more that 300 residues in 
length and contain the Asp-Thr-Gly 
sequence in each domain which forms the 
active site, and effectuates the cleavage 
reaction ( Davies, D. R 1990; Pearl, L. 
H..1987). The HIV protease sequence is no 
more than 99 amino acid long and contains 
only one of the required triad Asp-Thr-Gly, 
which was later confirmed that the active 
form of the HIV protease is a homo-dimer of 
198 amino acids by X-ray crystallographic 
determinations (Pearl, 1987; Navia, 1989; 
Wlodawer, 1989; Lapatto, 1989). 
The HIV aspartic protease (HIV-PR) 1 is 
a key enzyme in the virus life cycle and it 
becomes an indispensable part of 
conventional HAART or combination 
therapy for AIDS patients (Balzarini,  1996). 
This enzyme was earlier perceived as a 
promising therapeutic target and its 
inhibition has been successfully used in the 
treatment of AIDS. Despite this achievement, 
the emergence of strains resistant to the 
currently available commercial inhibitors, the 
high cost of these drugs and its associated 
toxicity has driven a continuous interest in 
the development of new inhibitors. The 
search for new inhibitors often includes high 
throughput screening programs for detecting 
HIV-PR inhibitor candidates. In order to 
identify and evaluate potential inhibitors 
either from natural sources or from rational 
designs, some groups have developed HIV-
PR activity assays 
Numerous data are available which show 
a great potential of natural products in 
having natural HIV-Protease inhibitors as, 
Limonin and Nomilin isolated from Citrus 
sps (Battinelli, 2003), Maslinic acid from 
Geum japonicum (Xu, 1996), Oxygeneted 
triterpenes (Ganoderic acid-α) from 
Ganoderma lucidum (Mekkawy, 1998), Ursolic 
acid and Uvaol from Crataegus pinatifida,(Min, 
1999) and many other compounds are in pipe 
line.  
As a part of our prescreening program to 
investigate HIV-Protease inhibitory activity 
of crude plant extracts, various extracts of 
Adhatoda vasica were examined, which is 
used in Ayurvedic medicinal system to cure 
diseases known to be of viral origin. An 
indirect approach was used for screening 
HIV-Protease inhibitors through pepsin 
activity inhibition assay from crude plant 
extract, as many paper support the evidence 
in the resemblance in the activity of HIV-
Protease and Enzyme Pepsin (Toh, 1985; 
Pearl, 1987; Seelmeier, 1988; Navia, 1989; 
Wlodawer, 1989; Lapatto, 1989; Davies, 1990; 
Fitzgerald, 1990).  
 
2. Materials and Methods 
Chemical required: Enzyme Pepsin 
(Himedia), Hemoglobin (Himedia), plants 
extract, Sodium Acetate tri hydrates 
(Qualigens), Sodium Chloride (Himedia), Tri 
Chloro Acetic acid (TCA) (Sdfine), Ethanol, 
Methanol, Chloroform and experimental 
plant material. Acetate buffer was prepared 
by 50 Mm Na Acetate tri hydrate and 0.1 M 
NaCl with pH- 3.5. 
 
Instruments required 
 Spectrophotometer - Karry 100, Sigma 
table centrifuge for 14000 rpm, Rami for 8000 
rpm, Micropipette 5-40 µl, 40-200 µl, 200-1000 
µl, Eppendorff (1.75ml), Mixer grinder, 
Mortar pestle, electronic balance. 
 
Plants extract preparation 
The plant material was collected from 
north-west part of Uttar Pradesh state of 
India. Whole aerial part of fresh plant 
material was taken, and washed properly 
with distilled water (DW). 5 g of sample was 
cut  into small pieces and ground properly in 
mortar and pestle. 10 ml of DW was added to 
get fine paste and centrifuged for 30 min at 
8000 rpm. Supernatant was collected and 
used as a crude extract of plant material.     
Enzyme Pepsin activity inhibition Assay: 
- Pepsin has a quite close resemblance in 
proteolytic activity with HIV-1 protease one 
of key enzyme of  HIV-1 life cycle as both of 
them belong to same Aspartate enzyme 
family (Maria del et. al., 2004). This enzyme 
was used as a substitute of HIV-1 protease to 
check out anti HIV activity of plants extract 
in this experiment.  
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Procedure 
For this assay, 50µg pepsin, 800µg 
hemoglobin and different crude plant 
extracts were taken in 500µl of reaction 
mixture. The mixture was allowed to 
incubate at 370C, after 20 min 700µl of 5% 
TCA was added to stop the reaction. It was 
then centrifuged at 14000 g for 5 min and the 
supernatant was collected. Optical Density 
(OD) was recorded spectrophotometrically at 
280 nm. 
Separate blanks were used for both 
positive and negative control as well as for 
sample. For positive control enzyme and 
substrate were taken and followed the above 
procedure, and for negative control pepstatin 
A was taken as a well known inhibitor of 
both Pepsin and HIV-Protease (Aoyagi, 
T.1978). Each sample was taken in triplicate, 
so this assay gives reproducible results. 
 
 
Several experiments were performed to get optimum activity of enzyme:_ 
 
Parameter  optimum range  
pH  2- 4 
Incubation temperature 37 0 C 
Incubation period 20min. 
Centrifugation 14000 g. 
Reaction volume 500 µL 
 
 
 3. Results 
Four extracts (aqueous, ethanol, 
methanol, and chloroform) of plant were 
prepared in the current study. Active 
component was present in aqueous extract 
while the organic extract have very rare 
active component with no or negligible toxic 
effect.  Aqueous extract of A. vasica extract 
showed a significant effect on the enzymatic 
activity of pepsin, that was upto 99% (table-1) 
and other plant extracts did not show any 
effect on the enzymatic activity of pepsin. 
Chloroform extract shown least effect on the 
enzymatic activity of pepsin. 
 
Table1 
S.No. Experimental sample Absorbance at 280 nm 
1 (+) Control (absence of  any inhibitor) 0.4054 ±0.0085 
2 (-) Control (presence of Pepstatin A) 0.0018 ±0.0085 
3 Presence of A. vasica aqueous extract. 0.0053 ±0.0085 
4 Presence of A. vasica ethanol extract 0.3506 ±0.0085 
5 Presence of A. vasica methanol extract 0.3433 ±0.0085 
6 Presence of A. vasica chloroform extract 0.4253 ±0.0085 
 
4. Discussion and conclusion 
AIDS remain the greatest public health 
challenges in the current world health sector. 
Currently, no reliable and user friendly 
treatment can be claimed to combat this 
diseases. The current anti‐HIV drugs that 
include reverse transcriptase (RT) and 
protease inhibitors have experienced drug 
resistance with HIV strains. This imposes the 
demand for the development of new drugs 
particularly of plant origin owing to their 
success as sources of antiHIV drugs. The use 
of plants for managing different diseases has 
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become a common practice since time 
immemorial with most of the people in the 
developing world relying on traditional 
medicines for their primary health care 
including management of HIV/AIDS. 
 
 
 
Figure-1 Bar (+) C (positive control) shows pepsin enzymatic activity in the absence of any inhibitor, bar (-) C 
(negative control) shows approximately 100% inhibition of enzyme activity in the presence of natural inhibitor 
Pepstatin A of enzyme Pepsin, Bar A shows the inhibition of enzyme activity by aqueous extract of Adhatoda vasica 
and bar B, C and D shows inhibitory effect of ethanol, methanol, and chloroform extracts on enzymatic activity of 
Pepsin respectively 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The main purpose of present study is 
prescreening of HIV-protease inhibitors from 
Adhatoda vasica, which is traditionally used in 
Ayurvedic system of medicine to cure 
different kinds of diseases, this eliminates the 
chances of toxic effect to human system. As 
shown in figure-1 aqueous extract of 
Adhatoda vasica showed a very significant 
inhibition on the enzymatic activity of pepsin. 
Medicinal properties A.vasica are already 
well documented as for cold, cough, 
whooping cough, chronic bronchitis and 
asthma. As various previous studies 
suggested the structural and a functional 
similarity between pepsin and HIV-Protease, 
plant extracts which have inhibitory activity 
of pepsin enzyme should also inhibit the 
activity of HIV-Protease.  HIV-Protease plays 
a significant part in the replication cycle of 
HIV, and its dysfunction leads to release of 
immature and noninfectious virion particles. 
This makes it an indispensable part of 
current conventional HAART or combination 
therapy. This study can append one more 
option as an alternative inhibitor of HIV-
protease to resolve resistance problem of this 
virus upto some extent. But it still needs 
further consideration of isolation and 
chemical analysis of active component of its 
plant extract. 
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